Phase 1/2Recruiting
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer (MRD)
Phase II Study Evaluating the Effect of IMNN-001 on Second Look Laparoscopy (SLL) in Combination With Bevacizumab (BEV) and Neoadjuvant Chemotherapy (NACT) in Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Sponsor
- Imunon (Industry)
- Enrolment
- 30 planned
- Conditions
- Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
- Interventions
- Paclitaxel; Carboplatin; Bevacizumab; IMNN-001
- Ages
- adults, older adults
- Registry
- NCT05739981
Full record on ClinicalTrials.gov
From the registry
This is a 1:1 randomized, open label, multi-center phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to chemotherapy + BEV compared to chemotherapy + BEV alone.
Primary outcomes
- Minimal Residual Disease
History
Study completion expected
Primary completion expected
Last registry update
Registered
Started